Category: Clinical Trials & Real-World Evidence Written and Reviewed By: Pharmacally Medical News Desk At European Society of Cardiology Congress 2025 in Madrid happening between August 29 to 1 September 2025, Novo Nordisk reported that Wegovy (semaglutide 2.4 mg) was linked to a 57% lower risk of heart attack, stroke, or death compared with tirzepatide in people with obesity and established cardiovascular disease who do not have diabetes, based on a large U.S
Menopause is associated with low ovarian but increased peripheral estrogens and a relative rise in androgen levels
CHP: cumene hydroperoxide
Notably, testing in animals also showed that it worked without some of the drugs side effects such as nausea, constipation and significant loss of muscle mass
If you were taking Ozempic for diabetes, stopping the medication can lead to blood sugar increases or fluctuations
There are nutritional options you can turn to that could provide the support your body needs